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Abstract  
Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid 
neoplasms). It is characterized by a progressive accumulation of functionally incompetent 
lymphocytes. Patients with leukemia often seek unconventional treatments not prescribed by 
hematologist in order to improve their cancer treatment outcome or to manage symptoms. In the 
present report, a 76-year-old patient was diagnosed with B-cell chronic lymphocytic leukemia (B-
CLL). Beetroot-carrot juice is used as a complementary and or/ alternative therapy used in 
conjunction with conventional leukemic treatment (chlorambucil) that has been a standard first-line 
chemotherapeutic agent for patients with CLL and known to have serious and undesirable side-
effects. After one month and 15 days of administration of beetroot-carrot juice therapy, the patient 
had improved appetite, a sense of general well-being and increased vigor daily activities. 
Furthermore, beetroot-carrot juice was used as an adjuvant to chlorambucil resulted in a substantial 
reduction in leukocytes and lymphocytes count in peripheral blood and improvement in the relevant 
biochemical parameters.  Beetroot-carrot juice can be used as an effective treatment for CLL alone 
or in combination with chlorambucil when taken orally with regular diet on daily basis. 
 
 
 
 
 
 
Introduction 
 
Chronic lymphocytic leukemia (CLL) is an 
indolent lymphoproliferative disorder. It was largely 
considered to be a disease of slow progression and 
chlorambucil drug has been the standard treatment for 
many decades [1]. Most of the anti-cancer drugs 
currently used in chemotherapy can have serious and 
undesirable side-effects and may cause toxicity to 
normal cells. Efforts were made to develop effective 
alternative strategies that increase the therapeutic 
efficacy and minimize the systemic toxicity of the 
conventional chemotherapeutic agents [2].  Thus, 
natural treatments could support existing 
chemotherapy agents’ treatment of leukemia, if their 
use could reduce side effects without compromising 
efficacy. Promising natural sources of such new 
agents could be found in common foods which contain 
bioactive compounds with potential anticancer 
properties [3]. The beetroot (Beta vulgaris L.), locally 
known as Shamandar, is a vegetable plant and 
belongs to family Amaranthaceae. Studies that 
focused on anticancer activities of beetroot extract, in 
animal models, have unraveled their potential benefits 
as chemopreventive and chemotherapeutic agents. 
Studies by Dr. Sandor (Alexander) Ferenczi (Nobel 
Prize winner) was pioneered of the use of beetroot 
juice as a cancer therapy in the nineteenth century 
and studied its strong anti-tumor effect as it contains a 
tumor inhibiting substance that he attributes to its 
natural red coloring agent, betaine [4]. Beetroot has 
many remarkable therapeutic uses as anticancer, 
hemostatic, antioxidative, antiradical, anti-
inflammatory and renal protective properties. In 
traditional medicine, carrots (Daucus carota) have 
been used as treatments for leukaemia and other 
cancers throughout history [5] and have previously 
been studied in other contexts as potential sources of 
anticancer agents [6].  
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In the current study we present a case report 
of CLL treated with a blend of beetroot- carrot juice 
either alone or in combination with antileukemic drug 
'Chlorambucil'. 
 
 
Case Presentation 
 
A- 76 -year-old female presented in the year 
2010 with a history of fatigue in the last 1-2 years that 
was progressive and worsened on exertion. At first, 
the fatigue did not prevent her from doing her daily 
activities, but later, she became somewhat less active. 
She was complaining of symptoms of weakness, 
intermittent upper back pain. She denied having other 
clinical symptoms as weight loss, night sweats, fevers, 
cough, chest pain, abdominal pain, dizziness, and 
syncope. On physical examination, no cervical, 
axillary, or inguinal lymphadenopathy was observed. 
No palpable hepatomegaly or splenomegaly was 
detected. Initial laboratory data undertaken on 8 th 
January 2010 revealed a high level of Leukocytes and 
lymphocytes. Haematology report was as follows: 
Hemoglobin level,11.6 g/dL; Red Cell Count, 3.94 
mil/cmm; mean corpuscular volume, 88.3 fL; 
Leukocytes count, 46,700/cmm. ; Lymphocytes, 85%; 
monocytes, 2.9%, eosinophils, 0.7%; and platelet 
count, 186 ×103/μL. The patient's creatinine was 
normal at this stage (1.04 mg/dL), blood urea was 55 
mg/dL. 
The patient was diagnosed with B-cell chronic 
lymphocytic leukemia (B-CLL) based on incidental 
finding of lymphocytosis, and the typical lymphocyte 
surface markers with positive CD19, CD5, CD23, and 
weak expression of surface lambda. Flow cytometry 
immunophenotyping of peripheral blood, performed in 
14 th January 2010 at Quest Diagnostics- West Hills, 
CA, USA, revealed the presence of an abnormal 
CD19, CD5, CD23, lymphoid cell population. She was 
taken to a specialized haematology clinic on 7th April 
2010 and the hematologist recommended repeating 
the immunophenotyping test. The test was repeated in 
19 th April 2010 and the phenotypic pattern gives the 
case a score of ‘5’ in the WHO scoring system for 
CLL, thus confirming a case of B-Kappa CLL (Table 
1). 
Table1: Flow cytometry immunophenotyping findings 
Study Results 
 
Flow Cytometry Analysis in  
14
th
 January 2010 
 
An abnormal cell population comprises 67% 
of total cells. The coexpression of CD5 and 
CD23 in B- cells (CD19+) is consistent with 
chronic lymphoproliferative disorder (usually 
chronic lymphocytic leukemia CLL). 0% of 
the CD19 positive lymphocytes express 
CD38.   
  
Flow Cytometry Analysis in  
19
th
  April 2010 
CD19: 90.9%, CD5: 52.7%, FMC7: 11.0%, 
CD3: 7.65%, CD10:1.15%,CD38: 6.72%, 
CD23:70.9%, Anti Kappa: 87.9%, Anti 
lambda:7.57%. 
  
As the patient was physically unfit for FCR 
(fludarabine, cyclophosphamide, rituximab) therapy, 
the haematologist treated her with single-agent 
chemotherapy (chlorambucil) as a mild chemotherapy 
that is currently established as standard treatment [7]. 
The three treatment phases either with 
chlorambucil drug, beetroot-carrot juice, or both 
exhibited different potency: 
 
Phase 1 - Chlorambucil protocol 
The patient received chlorambucil 4 mg/ day 
for a period of 8 months from 19th of April 2010 to 
16th December 2010. Total leukocytes count declined 
from 80,000 to 17,800/cmm (Fig. 1). During the 
course of the treatment, all CBCs showed absolute 
lymphocytosis and were not resolved as lymphocytes 
decreased only from 88 to 70% as demonstrated in 
Fig. 2. Serum creatinine had fallen from 1.72 to 1.24 
mg/dL, but in the middle of the treatment it recorded a 
high value of 1.86 mg/dL. The patient remained 
clinically stable but with persistent fatigue. 
 
Figure 1:  Change in peripheral leukocytes count during the three 
treatment phases 
 
Phase 2 (first relapse) - Beetroot- carrot juice 
protocol  
Recurrence of the disease was observed on 
the 7 th May 2012 with rising count of leukocytes to 
61,200/cmm and lymphocytes to 88%.The patient 
refused to repeat the regimen of the chemotherapy 
drug chlorambucil and she was convinced to start a 
new treatment of consuming a natural juice composed 
of beetroot (Beta Vulgaris L.) blended with carrot 
(Daucus  Carota). The given dose was 330 ml of fresh 
raw beetroot- carrot juice blend and was administered 
orally (beetroot 200 g. + carrots 250 g.) two hours 
before breakfast. The juice taste was palatable and 
well tolerated. The juice was administered to the 
patient in daily doses once per day (6 times/ week) for 
duration of 1 month and 15 days. The patient was 
observed to have an increase in appetite, 
improvement in performance of daily activities along 
with lack of fatigue few days after consuming the 
juice. 
In Fig. 1 & 2, it can be seen that by 
introducing 330 ml of the beetroot- carrot juice to the 
patient 6 times/week for duration of 1 month 15 days 
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(from 7th May 2012 to 20th June 2012) had the 
potency to decrease leukocytes count from 
61,200/cmm to 34,800/cmm and lymphocytes from 
88% to75% on the 20th June 2012. There was also a 
reduced level of uric acid in blood by 11.57% (9.5 to 
8.4 mg/dL).  
 
Figure 2:  Change in peripheral lymphocytes count during the three 
treatment phases 
 
The patient discontinued the beetroot- carrot 
juice for a period of 1 month during which she was not 
cooperative; however on the 20th of July 2012 she 
resumed the juice. Same dose of the juice was given 
once per day but only twice/week for a period of 2 
months and 11 days till 1st of October 2012. 
On the 1st October 2012, leukocytes count 
started to increase and reached a level of 47,800/ 
cmm and lymphocytes recorded a value of 88%.   
 
Phase 3 (second relapse) - Chlorambucil + 
beetroot- carrot juice protocol 
The patient stopped the juice regimen for 1 
year, 7 months and 9 days as she complained and get 
bored of drinking the juice daily. The patient presented 
with a very serious clinical situation. She had fever 
and the leukocytes count reached a high level. On the 
15th April 2014, the patient developed prominent 
leukocytosis (149,800/cmm) with absolute 
lymphocytosis (96%). The RBCs and Hb dropped to 
2.9 mil/cmm and 9.2 g/dL respectively. Platelet count 
was 144,000/ cmm (normal value). The uric acid 
reached a level of 9.1 mg/dL. The haematologist has 
treated the patient with chlorambucil protocol 4 mg/ 
day for a period of one month. The haematologist 
recommended that the patient should be switched to a 
salvage therapy if she will not respond to this drug 
regimen as a single agent as initial therapy. 
On 10th May 2014, a rapidly rising in 
leukocytes count occurred with a suppression of 
haemoglobin (Fig. 3) and platelet production (Fig. 5). 
The leukocytes count reached a high level of 185, 
400/cmm; lymphocytes declined to 90% (Fig. 1, 2) 
despite the treatment with chlorambucil. The Lactate 
dehydrogenase (LDH) which is a general indicator of 
the existence and severity of acute or chronic tissue 
damage, reached a high level of 360 U/L. The 
haematologist doubled the dose of chlorambucil to 8 
mg/ day. The beetroot- carrot juice (330 ml) was then 
introduced daily; 6 times per week, in combination 
with the chlorambucil protocol 8 mg/day. 
 
Figure 3:  Change in hemoglobin during the three treatment phases 
 
From the 10th of May to the 16th of June 
2014, the patient's leukocytes count had gradually 
declined from 185,400/cmm to 25,600/cmm (Fig. 1); 
lymphocytes count was also reduced from 90% to 
78% (Fig. 2). The Hb and RBCs reached a level of 8.7 
g/dL and 2.6 mil/cmm, respectively (Fig. 3, 4). Her 
renal function improved as blood urea, serum 
creatinine and uric acid dropped from 60 to 52 mg/dL, 
1.3 to 1.2 mg/dL and 4.4 to 3.3 mg/dL, respectively. 
There was no evidence of hemolysis as reticulocytes 
count decreased from 3.2% to 2.4% and direct 
Coombs’ test was negative. It was also noticed that 
LDH decreased to a level of 197 U/L. 
 
Figure 4:  Change in RBCs during the three treatment phases 
 
During the three treatment phases, 
hematological parameters including Hb and RBCs 
recorded low values below normal levels (Fig. 3 & 4), 
whereas platelets count was fluctuating between 
normal and below normal levels indicating mild 
thrombocytopenia (Fig. 5).  
The patient refused to cooperate and stopped 
taking the juice again from August 2014 to December 
2014. She followed the initial treatment with 
chlorambucil alone (8 mg/day) without the juice. A 
complete regression of CLL documented by a 
normalization of the peripheral leukocytes and 
lymphocytes count was observed, but accompanied 
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by deterioration in renal function demonstrated by an 
increase in serum urea (155 mg/dL) and serum 
creatinine (1.8 mg/dL).  It was unlikely to have been 
due to uric acid nephropathy as the serum uric acid 
was not elevated (4.0 mg/dL).  
 
Figure 5:  Change in platelet count during the three treatment 
phases 
 
The patient resumed taking the beetroot-
carrot juice for one month daily. Kidney function was 
improved; her serum urea and creatinine level were 
reduced (77 mg/dL and 1.3 mg/dL, respectively). The 
total and ionized serum calcium concentration 
remained normal (8.6 mg/dL and 4.9 mg/dL 
respectively). Serum Na+ and K+ level recorded 
normal values (130 mmol/L and 5.1 mmol/L, 
respectively). 
 
 
Discussion  
 
In the present study, the effect of beetroot-
carrot juice on leukocytes and lymphocytes count 
either administered alone or in combination with the 
antileukemic drug chlorambucil was reported. 
From Fig. 1 & 2, we have been able to 
demonstrate in our patient that administration of 
beetroot-carrot juice alone (phase 2) induced a 
reduction in peripheral blood leukocytes and 
lymphocytes count by 43.13% and 14.7% respectively 
and a partial remission was achieved 1 month 15 days 
after the treatment. There was a reduction in the level 
of uric acid. It was established that the elevated level 
of uric acid (hyperucimea) was caused by tumor lysis 
syndrome (caused by the breakdown products of 
dying cancer cells) of leukocytes cells [8]. Stopping 
the beetroot-carrot juice for 1 month, then resumption 
of the juice for another 2 months and 11 days, leads 
to an increase in leukocytes and lymphocytes counts 
and increase in uric acid level.  
After the second relapse, the patient had not 
responded to chlorambucil treatment alone from 15th 
April 2014 till 10th May 2014. In contrast, the 
combined treatment of the antileukemic drug 
chlorambucil and beetroot-carrot juice for 1 month and 
6 days recorded a significant reduction in total 
leukocytes and lymphocytes count by 86.19% and 
13.3%, respectively. This result provides evidence for 
the strong effectiveness of the combination treatment 
of chlorambucil and beetroot-carrot juice in eliminating 
malignant leukemic cells. Chlorambucil may produce 
its antitumor effect in CLL by inducing apoptosis-
associated membrane changes that resulted in rapid 
clearance of the apoptotic cells by the immune system 
[9]. It was shown from our study that beetroot-carrot 
juice may act in synergism with chlorambucil by 
lowering peripheral leukocytes and lymphocytes 
count. Furthermore, the toxic side effects associated 
with chlorambucil was minimized by combining the 
dosing regimen (8 mg/day) with the beetroot-carrot 
juice, building up the patient’s tolerance to the drug. 
Beetroot -carrot juice reduced the most frequent signs 
of gastrointestinal tract damage including vomiting, 
diarrhea, anorexia and stomatitis in response to 
chlorambucil [10]. Improvement in renal function 
followed this combined treatment was observed. 
Therefore, Beetroot-carrot juice presented a 
successful treatment as it prevented renal impairment 
due to leukemic infiltration of the kidneys that may 
result from the use of chlorambucil alone [11].  
Many studies showed that red beetroot (Beta 
vulgaris L.) extract, approved by Food and Drug 
Administration and European Union as red food color 
E162, reduced multi-organ tumor formations in 
various animal models when administered ad libitum 
in drinking water [12]. Many research exhibited the 
cytotoxic effects and antiproliferative activity of 
betanin, the major constituent of the red beet-derived 
betalains on different tumor cell lines of human origin 
[13]. It should be noted that betacyanins, among the 
beetroot betalain constituents, are the most important 
and potent compound responsible for the observed 
anticancer effects [14].  
Another study reported that betanin, isolated 
from the fruits of Cactus Opuntia ﬁcus-indica, similar 
to the betanin isolated from red beetroot [15] induced 
apoptosis in the human chronic myeloid leukemia cell 
K562 line [16]. This study have demonstrated that 
betanin entered K562 cells and made biochemical 
alterations, and induced the initiation of apoptosis. 
Furthermore, the high content of folic acid (15.8 mg/g 
dry matter) is another nutritional feature of beetroot 
which may account for its anti-proliferative and 
immunomodulatory activity [17]. 
Researchers reported the synergistic 
cytotoxic effect of red beetroot with doxorubicin in 
human prostate (PC-3), pancreas (PaCa), and breast 
(MCF-7) cancer cell lines. These results suggested 
that beetroot extract enhance the therapeutic efficacy 
of the potent chemotherapeutic drug (doxorubicin) 
[18].  
β-carotene, lutein and polyacetylenes derived 
from carrot are bioactive compounds shown to have 
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anticancer activities. They have effects on induction of 
apoptosis and inhibition of cellular proliferation. 
Treatment of leukemia cell lines with carrot juice 
extract induced apoptosis and inhibited progression 
through the cell cycle. Lymphoid cell lines were 
affected to a greater extent than were myeloid cell 
lines and normal hematopoietic stem cells were less 
sensitive than most cell lines [19]. 
In the present study, red blood cells were 
found to be reduced in the patient during the three 
treatment phases (Fig. 4). This may be due to less 
production of RBCs in bone marrow or their higher 
degradation in spleen. These results are consistent 
with previous studies [20, 21].   
It has been suggested that the kidney may act 
as a sanctuary site for leukaemic cells in response to 
treatment with chlorambucil alone [22] which may 
explain our findings of worsening kidney function 
despite hematological remission was achieved after 
stopping the juice. Lymphocytic infiltration of the 
kidney may be considered as a possible cause. This 
result confirms that treatment with beetroot-carrot 
juice and chlorambucil was effective in the present 
case in protecting the kidneys. The betaine 
component of beetroot is as an organic osmolyte. It 
accumulates in the kidney [23] from exogenous origin 
to protect cells from high concentrations of 
electrolytes [24] and urea [25]. Beetroot-carrot juice 
may then be an effective treatment when given alone 
or in combination with chlorambucil, leading to 
improvement in renal function. 
Our novel therapy leads the postulation that 
natural food product with known anticancer activity as 
beetroot-carrot juice, when used in right combination 
and dose could enhance the therapeutic efficacy of 
the potent antileukmic drug chlorambucil, by reducing 
its toxic side-effects. A possible synergistic effect of 
consumption of beetroot-carrot juice with chlorambucil 
resulted in a substantial improvement in renal function 
by acting as a kidney cleanser and protects the 
patient from renal impairement. Furthermore, 
beetroot-carrot juice could be used as natural 
alternative treatment for CLL when it was daily 
consumed as it has an antileukemic and anticancer 
effect.  
Beetroot-carrot juice might have promising 
therapy strategies in treating B-CLL and that its 
combination with chlorambucil could improve the 
effectiveness of the drug and reduce its toxic side 
effects. 
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